Eprenetapopt联合阿扎胞苷治疗TP53突变骨髓增生异常综合征
这项Ib/II期研究评估了Eprenetapopt联合阿扎胞苷在TP53突变MDS或伴20%-30%骨髓原始细胞的AML患者中的安全性、推荐II期剂量和疗效。55例患者中总缓解率71%,完全缓解率44%;MDS患者缓解率73%、完全缓解率50%。联合治疗耐受良好,在TP53突变MDS和寡原始细胞AML中产生高临床缓解率和分子缓解。
要点
- Eprenetapopt联合阿扎胞苷在TP53突变MDS中总缓解率73%,完全缓解率50%
- 仅检出TP53突变(二代测序)患者完全缓解率更高(69% vs 25%;P=.006)
- 38%患者达完全分子缓解(变异等位基因频率<5%),中位总生存10.8个月
核心结论
- Eprenetapopt联合阿扎胞苷耐受良好,在TP53突变MDS和寡原始细胞AML中产生高临床缓解率和分子缓解。
研究设计与样本
- Ib/II期研究,纳入55例至少一个TP53突变的MDS(40例)、AML(11例)或MDS/骨髓增殖性肿瘤(4例)患者。
主要发现
- 总缓解率71%,44%达完全缓解;MDS患者缓解率73%(29例),完全缓解率50%(20例),细胞遗传学缓解率58%(23/40)。
- AML患者总缓解率64%(7例),完全缓解率36%(4例)。
- 仅二代测序检出TP53突变者完全缓解率更高(69% vs 25%;P=.006)。
- 缓解者TP53变异等位基因频率和免疫组化p53表达显著下降,21例(38%)达完全分子缓解(变异等位基因频率<5%)。
- 中位总生存10.8个月,缓解者 vs 非缓解者标志分析为14.6 vs 7.5个月(P=.0005);19/55(35%)接受异基因造血干细胞移植,中位总生存14.7个月。
关键数值与推荐
- 最常见≥3级不良事件:发热性中性粒细胞减少33%、白细胞减少29%、中性粒细胞减少29%。
临床怎么用
- 对于TP53突变MDS或伴20%-30%骨髓原始细胞的AML,可考虑Eprenetapopt联合阿扎胞苷以提高缓解率和分子缓解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Approximately 20% of patients with TP53-mutant myelodysplastic syndromes (MDS) achieve complete remission (CR) with hypomethylating agents. Eprenetapopt (APR-246) is a novel, first-in-class, small molecule that restores wild-type p53 functions in TP53-mutant cells. METHODS: This was a phase Ib/II study to determine the safety, recommended phase II dose, and efficacy of eprenetapopt administered in combination with azacitidine in patients with TP53-mutant MDS or acute myeloid leukemia (AML) with 20%-30% marrow blasts (ClinicalTrials.gov identifier: NCT03072043). RESULTS: Fifty-five patients (40 MDS, 11 AML, and four MDS/myeloproliferative neoplasms) with at least one TP53 mutation were treated. The overall response rate was 71% with 44% achieving CR. Of patients with MDS, 73% (n = 29) responded with 50% (n = 20) achieving CR and 58% (23/40) a cytogenetic response. The overall response rate and CR rate for patients with AML was 64% (n = 7) and 36% (n = 4), respectively. Patients with only TP53 mutations by next-generation sequencing had higher rates of CR (69% v 25%; P = .006). Responding patients had significant reductions in TP53 variant allele frequency and p53 expression by immunohistochemistry, with 21 (38%) achieving complete molecular remission (variant allele frequency < 5%). Median overall survival was 10.8 months with significant improvement in responding versus nonresponding patients by landmark analysis (14.6 v 7.5 months; P = .0005). Overall, 19/55 (35%) patients underwent allogeneic hematopoietic stem-cell transplant, with a median overall survival of 14.7 months. Adverse events were similar to those reported for azacitidine or eprenetapopt monotherapy, with the most common grade ≥ 3 adverse events being febrile neutropenia (33%), leukopenia (29%), and neutropenia (29%). CONCLUSION: Combination treatment with eprenetapopt and azacitidine is well-tolerated yielding high rates of clinical response and molecular remissions in patients with TP53-mutant MDS and oligoblastic AML.
引用
- Sallman DA, DeZern AE, Garcia-Manero G, et al. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol. 2021. PMID: 33449813. doi:10.1200/JCO.20.02341
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。